Author/Authors :
Roudi, Raheleh Oncopathology Research Center - Iran University of Medical Sciences, Tehran, Iran , Nemati, Hosein Department of Genetics - Subdiscipline of Biology - Payame Noor University, Tehran, Iran , Rastegar Moghadam, Mahsa Department of Medical Genetics and Molecular Biology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran , Sotoudeh, Mehdi Urology and Nephrology Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Narouie, Behzad Department of Urology - Zahedan University of Medical Sciences, Zahedan, Iran , Shojaei, Azadeh Department of Medical Genetics and Molecular Biology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran
Abstract :
Background: Prostate cancer is a complex condition in which both genetic and environmental factors concomitantly contribute to
the tumor initiation and progression. Recently, HOXB13 has been proposed as a susceptibility gene for prostate cancer.
Objective: The present study was conducted to determine the existence of potential variations in HOXB13 gene in Iranian men with
prostate cancer (PCa) compared to benign prostatic hyperplasia (BPH) cases.
Methods: HOXB13 genetic status was screened in 51 samples, including 21 blood and tissue of PCa cases, and compared to 30 cases
affected by BPH using PCR/sequencing. Then, the existence of potential association was investigated between genomic DNA alterations
in blood and tissue PCa specimens.
Results: Analysis of BPH tissues showed single nucleotide variations c.366C > T (rs) or c.513T > C (rs9900627) in exon 1, but not
in exon 2. Evaluation of PCa tissues revealed 2 cases with both synonymous c.366C > T and c.513T > C variants and 2 cases with the
synonymous c.366C > T variant in exon 1. The variants c.366C > T and c.513T > C, simultaneously or separately, were found in blood
samples of PCa patients. The novel variant c.127A > G in exon 2 was detected in 1 PCa blood sample. Our analysis indicated a significant
reciprocal correlation between HOXB13 mutation in the tissue and blood samples of PCa cases (p= 0.02).
Conclusion: The variants in exon 2 of HOXB13 may influence the risk of prostate cancer. Also, evaluation of HOXB13 mutation
may be considered as a novel marker for screening PCa. Further investigations are warranted to evaluate the clinical significance of
HOXB13 in Iranian population.
Keywords :
Iran , Variant , Benign prostatic hyperplasia , HOXB13 , Prostate cancer